journal
https://read.qxmd.com/read/38632652/outcomes-of-sentinel-node-biopsy-according-to-mri-response-in-an-association-with-the-subtypes-in-cn1-3-breast-cancer-after-neoadjuvant-systemic-therapy-multicenter-cohort-study
#1
MULTICENTER STUDY
Soong June Bae, Jung Whan Chun, Sae Byul Lee, Jai Min Ryu, Seok Jin Nam, Joon Jeong, Hyung Seok Park, Sung Gwe Ahn
BACKGROUND: This study investigated the feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant systemic therapy (NAST) in patients with initially high nodal burden. METHODS: In the multicenter retrospective cohort, 388 individuals with cN1-3 breast cancer who underwent NAST and had SLNB followed by completion axillary lymph node dissection were included. In an external validation cohort, 267 patients with HER2+ or triple-negative breast cancer (TNBC) meeting similar inclusion criteria were included...
April 17, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38627755/meeting-abstracts-from-the-british-society-of-breast-radiology-annual-scientific-meeting-2023
#2
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 17, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38610016/metabolomics-assisted-by-transcriptomics-analysis-to-reveal-metabolic-characteristics-and-potential-biomarkers-associated-with-treatment-response-of-neoadjuvant-therapy-with-tcbhp-regimen-in-her2%C3%A2-%C3%A2-breast-cancer
#3
JOURNAL ARTICLE
Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou, Xiaohua Zeng
BACKGROUND: This study aimed to explore potential indicators associated with the neoadjuvant efficacy of TCbHP regimen (taxane, carboplatin, trastuzumab, and pertuzumab) in HER2 + breast cancer (BrCa) patients. METHODS: A total of 120 plasma samples from 40 patients with HER2 + BrCa were prospectively collected at three treatment times of neoadjuvant therapy (NAT) with TCbHP regimen. Serum metabolites were analyzed based on LC-MS and GC-MS data...
April 12, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38609935/selective-omission-of-sentinel-lymph-node-biopsy-in-mastectomy-for-ductal-carcinoma-in-situ-identifying-eligible-candidates
#4
JOURNAL ARTICLE
Soong June Bae, Yoonwon Kook, Ji Soo Jang, Seung Ho Baek, Sohyun Moon, Jung Hyun Kim, Seung Eun Lee, Min Ji Kim, Sung Gwe Ahn, Joon Jeong
BACKGROUND: Sentinel lymph node biopsy (SLNB) is recommended for patients with ductal carcinoma in situ (DCIS) undergoing mastectomy, given the concerns regarding upstaging and technical difficulties of post-mastectomy SLNB. However, this may lead to potential overtreatment, considering favorable prognosis and de-escalation trends in DCIS. Data regarding upstaging and axillary lymph node metastasis among these patients remain limited. METHODS: We retrospectively reviewed patients with DCIS who underwent mastectomy with SLNB or axillary lymph node dissection at Gangnam Severance Hospital between January 2010 and December 2021...
April 12, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38605414/chitin-mediated-blockade-of-chitinase-like-proteins-reduces-tumor-immunosuppression-inhibits-lymphatic-metastasis-and-enhances-anti-pd-1-efficacy-in-complementary-tnbc-models
#5
JOURNAL ARTICLE
Robbe Salembier, Caro De Haes, Julie Bellemans, Kristel Demeyere, Wim Van Den Broeck, Niek N Sanders, Steven Van Laere, Traci R Lyons, Evelyne Meyer, Jonas Steenbrugge
BACKGROUND: Chitinase-like proteins (CLPs) play a key role in immunosuppression under inflammatory conditions such as cancer. CLPs are enzymatically inactive and become neutralized upon binding of their natural ligand chitin, potentially reducing CLP-driven immunosuppression. We investigated the efficacy of chitin treatment in the context of triple-negative breast cancer (TNBC) using complementary mouse models. We also evaluated the immunomodulatory influence of chitin on immune checkpoint blockade (ICB) and compared its efficacy as general CLP blocker with blockade of a single CLP, i...
April 11, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38594783/u2af2-snora68-promotes-triple-negative-breast-cancer-stemness-through-the-translocation-of-rpl23-from-nucleoplasm-to-nucleolus-and-c-myc-expression
#6
JOURNAL ARTICLE
Wenrong Zhang, Xinyue Song, Zining Jin, Yiqi Zhang, Shan Li, Feng Jin, Ang Zheng
BACKGROUND: Small nucleolar RNAs (snoRNAs) play key roles in ribosome biosynthesis. However, the mechanism by which snoRNAs regulate cancer stemness remains to be fully elucidated. METHODS: SNORA68 expression was evaluated in breast cancer tissues by in situ hybridization and qRT‒PCR. Proliferation, migration, apoptosis and stemness analyses were used to determine the role of SNORA68 in carcinogenesis and stemness maintenance. Mechanistically, RNA pull-down, RNA immunoprecipitation (RIP), cell fractionation and coimmunoprecipitation assays were conducted...
April 9, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38594742/serum-protein-profiling-reveals-an-inflammation-signature-as-a-predictor-of-early-breast-cancer-survival
#7
JOURNAL ARTICLE
Peeter Karihtala, Suvi-Katri Leivonen, Ulla Puistola, Elina Urpilainen, Anniina Jääskeläinen, Sirpa Leppä, Arja Jukkola
BACKGROUND: Breast cancers exhibit considerable heterogeneity in their biology, immunology, and prognosis. Currently, no validated, serum protein-based tools are available to evaluate the prognosis of patients with early breast cancer. METHODS: The study population consisted of 521 early-stage breast cancer patients with a median follow-up of 8.9 years. Additionally, 61 patients with breast fibroadenoma or atypical ductal hyperplasia were included as controls. We used a proximity extension assay to measure the preoperative serum levels of 92 proteins associated with inflammatory and immune response processes...
April 9, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38589932/clinical-factors-associated-with-patterns-of-endocrine-therapy-adherence-in-premenopausal-breast-cancer-patients
#8
JOURNAL ARTICLE
Kirsten M Woolpert, Julie A Schmidt, Thomas P Ahern, Cathrine F Hjorth, Dóra K Farkas, Bent Ejlertsen, Lindsay J Collin, Timothy L Lash, Deirdre P Cronin-Fenton
INTRODUCTION: Patients with hormone receptor positive breast cancer are recommended at least five years of adjuvant endocrine therapy, but adherence to this treatment is often suboptimal. We investigated longitudinal trends in adjuvant endocrine therapy (AET) adherence among premenopausal breast cancer patients and identified clinical characteristics, including baseline comorbidities and non-cancer chronic medication use, associated with AET adherence. METHODS: We included stage I-III premenopausal breast cancer patients diagnosed during 2002-2011 and registered in the Danish Breast Cancer Group clinical database who initiated AET...
April 8, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38566222/correction-mcl-1-confers-protection-of-her2-positive-breast-cancer-cells-to-hypoxia-therapeutic-implications
#9
Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, Martin Sattler, Melissa Arn, Claudia Luckner-Minden, Henning Schulze-Bergkamen, Inka Zörnig, Frederik Marme, Andreas Schneeweiss, Michael H Cardone, Joseph T Opferman, Dirk Jäger, Klaus Podar
No abstract text is available yet for this article.
April 2, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38553763/establishing-conditions-for-the-generation-and-maintenance-of-estrogen-receptor-positive-organoid-models-of-breast-cancer
#10
JOURNAL ARTICLE
Michael U J Oliphant, Dipikaa Akshinthala, Senthil K Muthuswamy
Patient-derived organoid models of estrogen receptor-positive (ER+) breast cancer would provide a much-needed tool to understand drug resistance and disease progression better. However, the establishment and long-term maintenance of ER expression, function, and response in vitro remains a significant challenge. Here, we report the development of an ER+ breast tumor organoid medium (BTOM-ER) that conserves ER expression, estrogen responsiveness, and dependence, as well as sensitivity to endocrine therapy of ER+ patient-derived xenograft organoids (PDXO)...
March 29, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38553760/paradoxical-cancer-cell-proliferation-after-fgfr-inhibition-through-decreased-p21-signaling-in-fgfr1-amplified-breast-cancer-cells
#11
JOURNAL ARTICLE
Feng Chi, Jason I Griffiths, Aritro Nath, Andrea H Bild
Fibroblast growth factors (FGFs) control various cellular functions through fibroblast growth factor receptor (FGFR) activation, including proliferation, differentiation, migration, and survival. FGFR amplification in ER + breast cancer patients correlate with poor prognosis, and FGFR inhibitors are currently being tested in clinical trials. By comparing three-dimensional spheroid growth of ER + breast cancer cells with and without FGFR1 amplification, our research discovered that FGF2 treatment can paradoxically decrease proliferation in cells with FGFR1 amplification or overexpression...
March 29, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38553754/exploring-the-dynamic-interplay-between-exosomes-and-the-immune-tumor-microenvironment-implications-for-breast-cancer-progression-and-therapeutic-strategies
#12
REVIEW
Sahar Safaei, Manouchehr Fadaee, Omid Rahbar Farzam, Amirhossein Yari, Elham Poursaei, Cynthia Aslan, Sahar Samemaleki, Dariush Shanehbandi, Behzad Baradaran, Tohid Kazemi
Breast cancer continues to pose a substantial worldwide health concern, demanding a thorough comprehension of the complex interaction between cancerous cells and the immune system. Recent studies have shown the significant function of exosomes in facilitating intercellular communication and their participation in the advancement of cancer. Tumor-derived exosomes have been identified as significant regulators in the context of breast cancer, playing a crucial role in modulating immune cell activity and contributing to the advancement of the illness...
March 29, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38553702/factors-associated-with-overall-survival-in-breast-cancer-patients-with-leptomeningeal-disease-lmd-a-single-institutional-retrospective-review
#13
JOURNAL ARTICLE
Gerald Wallace, Ronak Kundalia, Ethan Vallebuona, Biwei Cao, Youngchul Kim, Peter Forsyth, Aixa Soyano, Inna Smalley, Yolanda Pina
BACKGROUND: Breast cancer-related leptomeningeal disease (BC-LMD) is a dire diagnosis for 5-8% of patients with breast cancer (BC). We conducted a retrospective review of BC-LMD patients diagnosed at Moffitt Cancer Center from 2011 to 2020, to determine the changing incidence of BC-LMD, factors which are associated with the progression of BC CNS metastasis to BC-LMD, and factors which are associated with OS for patients with BC-LMD. METHODS: Patients with BC and brain/spinal metastatic disease were identified...
March 29, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38532516/temporal-changes-in-mammographic-breast-density-and-breast-cancer-risk-among-women-with-benign-breast-disease
#14
JOURNAL ARTICLE
Maeve Mullooly, Shaoqi Fan, Ruth M Pfeiffer, Erin Aiello Bowles, Máire A Duggan, Roni T Falk, Kathryn Richert-Boe, Andrew G Glass, Teresa M Kimes, Jonine D Figueroa, Thomas E Rohan, Mustapha Abubakar, Gretchen L Gierach
INTRODUCTION: Benign breast disease (BBD) and high mammographic breast density (MBD) are prevalent and independent risk factors for invasive breast cancer. It has been suggested that temporal changes in MBD may impact future invasive breast cancer risk, but this has not been studied among women with BBD. METHODS: We undertook a nested case-control study within a cohort of 15,395 women with BBD in Kaiser Permanente Northwest (KPNW; 1970-2012, followed through mid-2015)...
March 26, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38532428/correction-the-novel-phosphatase-nudt5-is-a-critical-regulator-of-triple-negative-breast-cancer-growth
#15
Jing Qian, Yanxia Ma, William M Tahaney, Cassandra L Moyer, Amanda Lanier, Jamal Hill, Darian Coleman, Negar Koupaei, Susan G Hilsenbeck, Michelle I Savage, Brent D G Page, Abhijit Mazumdar, Powel H Brown
No abstract text is available yet for this article.
March 26, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38515208/birc5-expression-by-race-age-and-clinical-factors-in-breast-cancer-patients
#16
JOURNAL ARTICLE
Alina M Hamilton, Andrea Walens, Sarah C Van Alsten, Linnea T Olsson, Joseph Nsonwu-Farley, Xiaohua Gao, Erin L Kirk, Charles M Perou, Lisa A Carey, Melissa A Troester, Yara Abdou
PURPOSE: Survivin/BIRC5 is a proliferation marker that is associated with poor prognosis in breast cancer and an attractive therapeutic target. However, BIRC5 has not been well studied among racially diverse populations where aggressive breast cancers are prevalent. EXPERIMENTAL DESIGN: We studied BIRC5 expression in association with clinical and demographic variables and as a predictor of recurrence in 2174 participants in the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1113) and younger (< 50 years; n = 1137) participants with breast cancer...
March 21, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38515142/expression-and-splicing-based-multi-tissue-transcriptome-wide-association-studies-identified-multiple-genes-for-breast-cancer-by-estrogen-receptor-status
#17
JOURNAL ARTICLE
Julian C McClellan, James L Li, Guimin Gao, Dezheng Huo
BACKGROUND: Although several transcriptome-wide association studies (TWASs) have been performed to identify genes associated with overall breast cancer (BC) risk, only a few TWAS have explored the differences in estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) breast cancer. Additionally, these studies were based on gene expression prediction models trained primarily in breast tissue, and they did not account for alternative splicing of genes. METHODS: In this study, we utilized two approaches to perform multi-tissue TWASs of breast cancer by ER subtype: (1) an expression-based TWAS that combined TWAS signals for each gene across multiple tissues and (2) a splicing-based TWAS that combined TWAS signals of all excised introns for each gene across tissues...
March 21, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38515107/factors-associated-with-engraftment-success-of-patient-derived-xenografts-of-breast-cancer
#18
JOURNAL ARTICLE
Jongwon Lee, GunHee Lee, Hye Seon Park, Byung-Kwan Jeong, Gyungyub Gong, Jae Ho Jeong, Hee Jin Lee
BACKGROUND: Patient-derived xenograft (PDX) models serve as a valuable tool for the preclinical evaluation of novel therapies. They closely replicate the genetic, phenotypic, and histopathological characteristics of primary breast tumors. Despite their promise, the rate of successful PDX engraftment is various in the literature. This study aimed to identify the key factors associated with successful PDX engraftment of primary breast cancer. METHODS: We integrated clinicopathological data with morphological attributes quantified using a trained artificial intelligence (AI) model to identify the principal factors affecting PDX engraftment...
March 21, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38504374/tmem120b-strengthens-breast-cancer-cell-stemness-and-accelerates-chemotherapy-resistance-via-%C3%AE-1-integrin-fak-taz-mtor-signaling-axis-by-binding-to-myh9
#19
JOURNAL ARTICLE
Ran Hu, Yu Cao, Yuanyuan Wang, Tingting Zhao, Kaibo Yang, Mingwei Fan, Mengyao Guan, Yuekang Hou, Jiao Ying, Xiaowen Ma, Ning Deng, Xun Sun, Yong Zhang, Xiupeng Zhang
BACKGROUND: Breast cancer stem cell (CSC) expansion results in tumor progression and chemoresistance; however, the modulation of CSC pluripotency remains unexplored. Transmembrane protein 120B (TMEM120B) is a newly discovered protein expressed in human tissues, especially in malignant tissues; however, its role in CSC expansion has not been studied. This study aimed to determine the role of TMEM120B in transcriptional coactivator with PDZ-binding motif (TAZ)-mediated CSC expansion and chemotherapy resistance...
March 19, 2024: Breast Cancer Research: BCR
https://read.qxmd.com/read/38486203/breast-cancer-survivors-suffering-from-lymphedema-what-really-do-affect-to-corporeality-body-image-a-qualitative-study
#20
JOURNAL ARTICLE
Laura González-Fernández, Carlos Romero-Morales, Beatriz Martínez-Pascual, Angela Río-González, Ester Cerezo-Téllez, Inmaculada López-Martín
Breast cancer-related lymphedema is currently one of the most serious complications that most affect the quality of life of women undergoing breast cancer. The aim of this study was to explore in-depth the experience of women who suffer from lymphoedema after breast cancer and how does this condition affect corporeality, with no judgements. For this purpose, a qualitative methodology was followed. In-depth interviews, interviewer's field notes and participants' letters were used for data collection. The participants were twenty Spanish women with lymphoedema after overcome a breast cancer in the past...
March 14, 2024: Breast Cancer Research: BCR
journal
journal
34908
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.